FDA Peptide Update: Category 2 Removals Explained FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of FDA Issues Warning: Compounding Certain Bulk Drug Substances May Pose Major Legal and Patient Safety Risks Lengea BPC 157 Banned: Key Facts on the Latest FDA Decision The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Valor Compounding Pharmacy Inc. Berkeley, CA. Untitled Letter issued 03 23 2023